CRP and Hypoalbuminemia: Instead of delaying lifesaving treatment, the authors highlight the importance of recognizing iMCD early on based on laboratory data (elevated ALP, normal immunoglobulin levels, increased CRP, and hypoalbuminemia) and giving siltuximab as soon as possible [12].